➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Dow

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METOLAZONE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Metolazone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00007592 Hypertension Screening and Treatment Program Completed VA Office of Research and Development N/A 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00649051 Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg Completed Mylan Pharmaceuticals Phase 1 2002-12-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions.
NCT00649181 Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg Completed Mylan Pharmaceuticals Phase 1 2003-10-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose administration under fasting conditions.
NCT00650195 Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg Completed Mylan Pharmaceuticals Phase 1 2004-02-01 The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Metolazone

Condition Name

Condition Name for Metolazone
Intervention Trials
Healthy 3
Acute Heart Failure 3
Acute Decompensated Heart Failure 2
Congestive Heart Failure 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Metolazone
Intervention Trials
Heart Failure 10
Respiratory Insufficiency 1
Hypernatremia 1
Renal Insufficiency, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Metolazone

Trials by Country

Trials by Country for Metolazone
Location Trials
United States 23
Italy 2
Puerto Rico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Metolazone
Location Trials
West Virginia 2
Tennessee 2
Ohio 2
California 2
Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Metolazone

Clinical Trial Phase

Clinical Trial Phase for Metolazone
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Metolazone
Clinical Trial Phase Trials
Recruiting 4
Completed 4
Not yet recruiting 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Metolazone

Sponsor Name

Sponsor Name for Metolazone
Sponsor Trials
Mylan Pharmaceuticals 3
IRCCS San Raffaele 1
Virginia Commonwealth University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Metolazone
Sponsor Trials
Other 20
Industry 4
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
McKinsey
Medtronic
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.